CinRx Pharma is a biopharmaceutical company developing novel therapeutics that address substantial unmet medical needs across diverse disease indications. CinRx’s product candidate portfolio includes innovative and disruptive new molecular entities (NMEs) with novel drug delivery techniques.
To advance its growing R&D pipeline, the Company applies industry-leading formulation, preclinical, and CMC expertise in conjunction with clinical development services of Medpace, Inc, a leading global contract research organization (CRO). Led by CEO Jonathan Isaacsohn, MD, FACC, CinRx’s team possesses unparalleled expertise in pharmaceutical R&D, focused expedited clinical development for innovative therapies.
CinRx’s primary objective is to acquire and develop assets that will be attractive acquisition targets to large pharma and biotech companies. Assets are sourced in house, acquired, partnered, and/or in-licensed from partners. CinRx is creating a pipeline that is therapeutically diverse with pre-clinical and clinical stage assets.READ MORE
CinRx has numerous promising drugs in development and currently reviewing several potential candidates. With a highly-specialized network of external resources and industry experts, CinRx is able to identify key opportunities, spanning across various therapeutic areas and stages.READ MORE